Anti-DLL3 Monoclonal Antibody (Rovalpituzumab)
Anti-DLL3 Monoclonal Antibody (Rovalpituzumab)
Product Details
Product Details
Product Specification
| Host | Human |
| Clone Number | S-SC041 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG1,k |
| Application | Blocking of DLL3 signaling Functional assays |
| Reactivity | Hu |
| Purification | Protein A |
| Concentration | 5 mg/ml |
| Endotoxin | <1EU/mg |
| Conjugation | Unconjugated |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, containing no preservative |
| Stability & Storage | 2 to 8 °C for 2 weeks under sterile conditions; |
Background
Rovalpituzumab was an antibody-drug conjugate targeting the DLL3 protein, initially developed primarily for the treatment of small cell lung cancer. It consisted of a humanized monoclonal antibody that specifically recognized and bound to the DLL3 protein on the surface of tumor cells, conjugated via a cleavable linker to a potent cytotoxic agent (PBD dimer) known as D6.5. Its mechanism of action was akin to a "biological missile," delivering the toxin precisely into DLL3-expressing tumor cells; upon internalization and release, the toxin caused DNA damage and subsequent cancer cell death.
Picture
Picture
SEC-HPLC
